Near-infrared Spectroscopy Guided Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction

June 6, 2025 updated by: Manijeh Noori, Odense University Hospital
The aim of this study is to investigate whether near-infrared guided percutaneous coronary intervention in patients with acute myocardial infarction provides improved stent strut coverage at six months compared to conventionally angiography guided percutaneous coronary intervention.

Study Overview

Detailed Description

Background Myocardial infarction (MI) secondary to atherosclerotic coronary artery disease is mainly due to plaque-rupture with formation of a luminal thrombogenic material. Lesions responsible for MI are more frequently composed of lipid-rich plaques (LRP) in both culprit and in non-culprit lesions compared to lesions in patients with stable angina.

LRP is thought to be main precursor for future coronary events and may also have an impact on complications following percutaneous coronary intervention (PCI). It has been previously indicated that stent thrombosis (ST) and restenosis often occur when stenting a lipid-rich plaque. And if using angiography guidance only during PCI, there is a potential risk of implantation of a stent edge on a lipid pool, which can result in incomplete stent coverage of a lesion. The incidence of restenosis and ST may be related to the lesion characteristics, clinical presentation, antithrombotic treatment and stent design. Other factors may include inflammatory reaction to the polymer coating containing drug that delays vascular healing, insufficient stent strut coverage and incomplete stent apposition (ISA).

Invasive imaging modality can contribute to better understanding of the changes that occur in the vessel wall during stent implantation.

Intravascular ultrasound (IVUS) combined with a new imaging modality called near-infrared spectroscopy (NIRS) can identify LRP and provide a semi-quantitative estimate of amount of LRP present within selected region of interest. The method is excellent to identify ISA and improve stent implantation technique.

Optical coherence tomography (OCT) is a high resolution imaging modality that can analyze healing pattern after stent implantation such as stent strut coverage.

Method The study is designed as a prospective randomized trial conducted at a single center (Odense University Hospital). Patients with MI will be enrolled if they fulfill the criteria. The study is submitted and approved by The Regional Committees on Health Research Ethics for Southern Denmark (Project-ID: S-20200010) and Danish Data Agency (Journal nr.: 20/18008).

Eligible patients will be randomly assigned to either NIRS-guided PCI or conventual angiography-guided PCI with implantation of Everolimus-eluting Xience stent, which is CE marked. NIRS will be performed in both groups after predilation and stent implantation. In NIRS-guided group the analyses will be used to identify LRP, and to measure vessel wall diameter in reference segments and lesion length. In angiography-guided group the analyses will not be available for the PCI operator and are for observation purpose only. OCT will be performed in both groups after stent implantation, but will be only available for interpretation in NIRS-guided group. In case of reintervention in NIRS-guided group, a final OCT will be performed.

Optimal PCI criteria were following: 1) minimum stent area (MSA) ≥ 5.5 mm2 and ≥ 90% of the distal reference lumen area; 2) no major stent malapposition; 3) plaque burden < 50% at stent edge border; 4) LCBI4mm < 150 in reference segments; and 5) no major stent edge dissection. In case of 1-3, we recommended additional post-dilatation, and in case of 4-5 we recommended an additional stent.

A significant LRP was with lipid-core burden index (maxLCBI4mm) ≥ 150.

Patients will be contacted by telephone to evaluate the clinical situation and to reduce the potential risk of dropout. After 6 months OCT will be performed in both groups to evaluate stent strut coverage and vessel healing.

Statistics Assuming data are normally distributed, categorical data will be presented as numbers and frequencies and compared using chi2-test. Continuous data will be presented as mean ± SD and compared using Student t test. SPSS version 26.0 will be used for the statistical analysis.

Sample size calculation Based on a previous study IVUS-guided PCI in STEMI, the percentage of covered stent struts was 85.4%±7.9. We hypothesized that the coverage in angiography-guided group will be lower by 5.6% at 6 month. A sample size of 86 patients (43 patients in each group) was required for the study to have a power of 80% and two-tailed significance level of 0.05. We expected a dropout rate of 20%, and 104 patients were required to be recruited in the trial.

Sato N, Minami Y, Shimohama T, Kameda R, Tojo T, Ako J. Vascular response and intrastent thrombus in the early phase after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: An observational, single-center study. Health Sci Rep. 2019;2(1):e105.

Study Type

Interventional

Enrollment (Actual)

104

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Odense, Denmark, 5000
        • Manijeh Noori

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients with acute coronary syndrome (ST-elevation myocardial infarction and non-ST elevation myocardial infarction) referred for invasive coronary angiography and percutaneous coronary intervention at Department of Cardiology, Odense University Hospital (Odense, Denmark)

Exclusion Criteria:

  • participation in other randomized clinical trials
  • life expectancy < 1 year
  • allergy to aspirin, clopidogrel, ticagrelor or prasugrel
  • eGFR < 30 mL/min
  • tortuous and angiographically estimated extremely calcified lesions
  • ostial, left main and bifurcation lesions
  • lesions in a reference vessel diameter < 2.0 mm
  • hemodynamic instability
  • Scheduled for coronary artery bypass grafting

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: NIRS-guided PCI
Near-infrared Spectroscopy guided Percutaneous coronary intervention with implantation of drug-eluting stent
NIRS-guided PCI
Active Comparator: Angiography-guided PCI
Angiography-guided percutaneous coronary intervention with implantation of a drug-eluting stent
Angiography guided PCI

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of stent strut coverage
Time Frame: 6 months after index percutaneous coronary intervention
Proportion of stent strut coverage at 6 months follow up estimated by OCT
6 months after index percutaneous coronary intervention

Secondary Outcome Measures

Outcome Measure
Time Frame
Uncovered stent struts
Time Frame: 6 months after index percutaneous coronary intervention
6 months after index percutaneous coronary intervention
Persistent stent malapposition
Time Frame: 6 months after index percutaneous coronary intervention
6 months after index percutaneous coronary intervention
Maximal neointimal growth
Time Frame: 6 months after index percutaneous coronary intervention
6 months after index percutaneous coronary intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Lisette Okkels Jensen, MD PhD Prof, Odense University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2020

Primary Completion (Actual)

September 1, 2022

Study Completion (Actual)

March 2, 2023

Study Registration Dates

First Submitted

July 2, 2020

First Submitted That Met QC Criteria

July 2, 2020

First Posted (Actual)

July 7, 2020

Study Record Updates

Last Update Posted (Actual)

June 11, 2025

Last Update Submitted That Met QC Criteria

June 6, 2025

Last Verified

June 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Myocardial Infarction

Clinical Trials on Near-infrared spectroscopy (NIRS)

Subscribe